Aurobindo Pharma gets US approval to sell generic Omnicef

19 Dec 2007

1

Mumbai: Aurobindo Pharma Ltd has won regulatory approval to sell its cefdinir oral suspension, a generic version of Abbott Laboratories' antibiotic Omnicef, in the US.
 
The US Food and Drug Administration said in its website that it has allowed Hyderabad-based Aurobindo Pharma to sell the generic drug, which is used to treat ear, sinus, throat and skin infections.

Omnicef generated $637 million in sales last year for Abbott Park, Illinois-based Abbott.

Aurobindo Pharma, which has plans to emerge as a billion dollar company by 2009-10, is enhancing its presence in Europe by investing $100 million in phases.

The company is likely to buy two pharma companies worth Euro 10 million each, open offices in 10 countries and establish a packaging, warehouse and manufacturing hub in Malta.

Aurobindo also may make strategic investments worth $10 million in the Gulf Cooperation Council (GCC) countries.

It is also setting up an active pharmaceutical ingredients (API) manufacturing plant at Annapolis in Brazil investing around $8 million.

Aurobindo already has a manufacturing unit in New Jersey, in the US.

With over 117 filings to its credit, the company has emerged as a leader in filing drug master files (DMF) for APIs in the US. The company has filed over 107 abbreviated new drug applications (ANDAs) in the US.

Business History Videos

History of hovercraft Part 3...

Today I shall talk a bit more about the military plans for ...

By Kiron Kasbekar | Presenter: Kiron Kasbekar

History of hovercraft Part 2...

In this episode of our history of hovercraft, we shall exam...

By Kiron Kasbekar | Presenter: Kiron Kasbekar

History of Hovercraft Part 1...

If you’ve been a James Bond movie fan, you may recall seein...

By Kiron Kasbekar | Presenter: Kiron Kasbekar

History of Trams in India | ...

The video I am presenting to you is based on a script writt...

By Aniket Gupta | Presenter: Sheetal Gaikwad

view more